Pharma Buyout Tabled

Pfizer says it won’t continue its pursuit to purchase AstraZeneca—at least for now.

By | May 27, 2014

FLICKR, IMAGES MONEYThe impending acquisition that has kept those in the pharmaceutical industry at the edge of their seats for the last several weeks is not going to happen after all: following multiple rejected offers, Pfizer said Monday (May 26) that it will no longer pursue the purchase of AstraZeneca.

“We are now moving on,” Pfizer CEO Ian Read told The Wall Street Journal. But he remained vague about his firm’s future plans: “We have no idea whether we’d be interested in AstraZeneca at any point in the future.”

For now, AstraZeneca executives—who had rejected Pfizer’s most recent acquisition bid of around $119 billion in cash and stock, according to The New York TimesDealBook—are breathing a sigh of relief. “We welcome the opportunity to continue building on the momentum we have already demonstrated as an independent company,” AstraZeneca’s Chairman Leif Johansson said in a statement.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. So You’ve Been Mistaken as a White Nationalist
  2. Opinion: We Need a Replacement for Beall’s List
  3. Your Body Is Teeming with Weed Receptors
    Features Your Body Is Teeming with Weed Receptors

    And the same endocannabinoid system that translates marijuana's buzz-inducing compounds into a high plays crucial roles in health and disease outside the brain.

  4. Doctors’ Advice to Finish Antibiotics Overlooks Resistance
AAAS